Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 28, 2012, Pages 11390-11395

  Inceoglu, Bora ^a   Wagner, Karen M ^a   Yang, Jun ^b   Bettaieb, Ahmed ^a   Schebb, Nils H ^a   Hwang, Sung Hee ^a   Morisseau, Christophe ^a   Haj, Fawaz G ^b   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Analgesic drug; Cytochrome P450; Glucose homeostasis; Motor depressant; Soluble epoxide hydrolase inhibitor

Indexed keywords

1 (1 METHYLSULFONYL PIPERIDIN 4 YL) 3 (4 TRIFLUOROMETHOXY PHENYL)UREA; 1 TRIFLUOROMETHOXYPHENYL 3 (1 ACETYLPIPERIDIN 4 YL)UREA; 12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID; EPOXIDE HYDROLASE; FATTY ACID; GABAPENTIN; MORPHINE; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG POTENCY; GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MALE; METABOLOMICS; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SPINAL CORD; STREPTOZOCIN DIABETES;

AMINES; ANIMALS; BEHAVIOR, ANIMAL; CYCLOHEXANECARBOXYLIC ACIDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DRUG DESIGN; FATTY ACIDS; GAMMA-AMINOBUTYRIC ACID; GLUCOSE; HYPERALGESIA; INSULIN; LIPIDS; MALE; MODELS, CHEMICAL; PAIN; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD;

RATTUS;

EID: 84863957642     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1208708109     Document Type: Article

References (40)

1. Calcutt NA (2010) Tolerating diabetes: An alternative therapeutic approach for diabetic neuropathy. ASN Neuro 2:e00042.
2. Edwards JL, Vincent AM, Cheng HT, Feldman EL (2008) Diabetic neuropathy: Mechanisms to management. Pharmacol Ther 120:1-34.
3. Vinik AI, Erbas T (2001) Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med 68:928-930, 932, 934-944.
4. Said G (2007) Diabetic neuropathy - A review. Nat Clin Pract Neurol 3:331-340.
5. Sima AAF, et al. (1988) Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 319:548-555.
6. Johnson PC, Doll SC, Cromey DW (1986) Pathogenesis of diabetic neuropathy. Ann Neurol 19:450-457. (Pubitemid 16116478)
7. Brown MJ, Asbury AK (1984) Diabetic neuropathy. Ann Neurol 15:2-12. (Pubitemid 14224213)
8. Gilliatt RW, Willison RG (1962) Peripheral nerve conduction in diabetic neuropathy. J Neurol Neurosurg Psychiatry 25:11-18.
9. Courteix C, Eschalier A, Lavarenne J (1993) Streptozocin-induced diabetic rats: Behavioural evidence for a model of chronic pain. Pain 53:81-88. (Pubitemid 23137271)
10. Veves A, Backonja M, Malik RA (2008) Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis, and treatment options. Pain Med 9:660-674.
11. Lindsay TJ, Rodgers BC, Savath V, Hettinger K (2010) Treating diabetic peripheral neuropathic pain. Am Fam Physician 82:151-158.
12. Attal N, et al.; EFNS Task Force (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13:1153-1169. (Pubitemid 44581463)
13. Gore M, Dukes E, Rowbotham DJ, Tai K-S, Leslie D (2007) Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain 11:652-664. (Pubitemid 46818059)
14. Ahlgren SC, Levine JD (1993) Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience 52:1049-1055. (Pubitemid 23063547)
15. Inceoglu B, et al. (2006) Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci 79:2311-2319. (Pubitemid 44666069)
16. Inceoglu B, et al. (2008) Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci USA 105:18901-18906.
17. Chacos N, et al. (1983) The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Arch Biochem Biophys 223:639-648. (Pubitemid 13103208)
18. Capdevila J, Chacos N, Werringloer J, Prough RA, Estabrook RW (1981) Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proc Natl Acad Sci USA 78:5362-5366. (Pubitemid 12248586)
19. Liu JY, et al. (2010) Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 79:880-887.
20. Morisseau C, et al. (2010) Naturally occurring mono epoxides of EPA and DHA are bioactive antihyperalgesic lipids. J Lipid Res 51:3481-3490.
21. Imig JD, Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8:794-805.
22. Wagner K, Inceoglu B, Gill SS, Hammock BD (2011) Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: Novel mediators of pain reduction. J Agric Food Chem 59:2816-2824.
23. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD (2007) Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82:42-49. (Pubitemid 44880165)
24. Schmelzer KR, et al. (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102:9772-9777. (Pubitemid 40993644)
25. Node K, et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276-1279. (Pubitemid 29398616)
26. Schmelzer KR, et al. (2006) Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103:13646-13651. (Pubitemid 44413961)
27. Dobretsov M, Hastings SL, Romanovsky D, Stimers JR, Zhang JM (2003) Mechanical hyperalgesia in rat models of systemic and local hyperglycemia. Brain Res 960:174-183. (Pubitemid 36044574)
28. Aley KO, Levine JD (2001) Rapid onset pain induced by intravenous streptozotocin in the rat. J Pain 2:146-150. (Pubitemid 32550236)
29. Inceoglu B, et al. (2011) Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci USA 108:5093-5097.
30. Morley GK, Mooradian AD, Levine AS, Morley JE (1984) Mechanism of pain in diabetic peripheral neuropathy. Effect of glucose on pain perception in humans. Am J Med 77:79-82. (Pubitemid 14087919)
31. Luria A, et al. (2011) Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci USA 108:9038-9043.
32. Luo P, et al. (2010) Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther 334:430-438.
33. Jones PD, et al. (2005) Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal Biochem 343:66-75. (Pubitemid 40978610)
34. Spector AA, Norris AW (2007) Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292:C996-C1012. (Pubitemid 46442641)
35. Bernstrom K, Kayganich K, Murphy RC, Fitzpatrick FA (1992) Incorporation and distribution of epoxyeicosatrienoic acids into cellular phospholipids. J Biol Chem 267:3686-3690.
36. Jones PD, Tsai H-J, Do ZN, Morisseau C, Hammock BD (2006) Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett 16:5212-5216. (Pubitemid 44247687)
37. Iliff JJ, et al. (2010) Epoxyeicosanoid signaling in CNS function and disease. Prostaglandins Other Lipid Mediat 91:68-84.
38. Hendrich J, et al. (2008) Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA 105:3628-3633. (Pubitemid 351723603)
39. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN (1993) A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 10:276-281. (Pubitemid 23041744)
40. Ulu A, et al. (2012) Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. Br J Pharmacol 165:1401-1412.